Project Details
| Status | Active |
|---|---|
| Effective start/end date | 5/22/24 → 5/22/27 |
Funding
- Quintiles, Inc. (Prot #XL092-305 // Prot #XL092-305)
- Exelixis Inc. (Prot #XL092-305 // Prot #XL092-305)
Prot #XL092-305: A Phase 2/3, Randomized, Double-blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab vs Pembrolizumab in the First-line Treatment of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous
- Lorch, Jochen Hanns-Martin (PD/PI)
Project: Research project